The Cancer Therapy That Wasn't Supposed to Work in Solid Tumors
For decades, CAR-T therapy has crashed and burned against solid tumors. Allogene's off-the-shelf ALLO-316 just posted durable remissions in advanced kidney cancer that are still going past 18 months, and Wall Street is paying attention.
The Graveyard Nobody Escapes
Solid tumors have been the graveyard of CAR-T therapy for decades. The technology that revolutionized blood cancer treatment has repeatedly crashed and burned when pointed at the dense, hostile fortresses of solid tumors. Dozens of clinical trials. Billions of dollars. And until now, not a single allogeneic CAR-T product (one made from donor cells rather than the patient's own) had delivered durable remissions in metastatic solid tumors.
Allogene Therapeutics just changed that.
The company published Phase 1 data in the Journal of Clinical Oncology on July 15 showing that its off-the-shelf CAR-T therapy, ALLO-316, produced lasting remissions in patients with advanced kidney cancer. The longest response has been going for more than 18 months, and every single responder was still progression-free at the time of analysis.
That's not a typo. In a field littered with brief flickers of hope, these patients are still responding.
Why Solid Tumors Break Every CAR-T That Enters
To appreciate why this matters, you need to understand the problem. Think of blood cancers like fish swimming in an open lake: CAR-T cells (engineered immune cells that hunt cancer) can find and destroy them relatively easily. Solid tumors are more like a fortified castle surrounded by a moat, guarded walls, and archers on the ramparts.
The tumor microenvironment actively fights back against CAR-T cells. Dense tissue blocks them from getting in. Once they arrive, the tumor releases chemical signals that exhaust and disable them. Oxygen is scarce. Nutrients are depleted. It's like trying to run a marathon in a sauna while someone keeps turning off the oxygen.
First-generation CAR-T trials in solid tumors date back to the 1990s. Researchers have targeted HER2, mesothelin, GD2, and a long list of other surface proteins. The pattern has been depressingly consistent: occasional partial responses, short-lived improvements, and no FDA-approved product. Ever.
ALLO-316 doesn't just break this pattern. It does so with an product, which adds a whole extra layer of difficulty.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
off-the-shelf
Off-the-Shelf: The Manufacturing Revolution
Traditional CAR-T therapy is bespoke. Doctors extract a patient's own immune cells, ship them to a factory, engineer them, grow them, and ship them back. The whole process takes two to six weeks and costs roughly $373,000 to $475,000 per product. If a patient's cancer is progressing rapidly, they may not survive the wait.
Allogeneic CAR-T flips the script entirely. Healthy donor cells are engineered in large batches, frozen, and stored on shelves like inventory. When a patient needs treatment, the product is ready to ship. It's the difference between ordering a custom-tailored suit and buying one off the rack; except in this case, the rack version might save your life faster.
The trade-off? Donor cells can attack the patient's healthy tissue (graft-versus-host disease) or get rejected by the patient's immune system. ALLO-316 uses gene-editing technology called TALEN to knock out two genes that cause these problems, creating a product that's tolerable in someone else's body. Notably, zero cases of graft-versus-host disease were reported across the trial.
The Numbers That Matter
ALLO-316 targets a protein called CD70, which is highly expressed on clear cell renal cell carcinoma (the most common type of kidney cancer). The TRAVERSE trial enrolled patients with stage IV disease who had already failed both immunotherapy and targeted therapy. These are patients running out of options.
In the Phase 1b cohort, a single infusion produced a confirmed response rate of 25% across all patients. That's one in four people seeing their tumors meaningfully shrink.
But the real story is in the subgroup with high CD70 expression (a tumor proportion score of 50% or above). In those patients, the confirmed response rate climbed to 31%. Nearly half, about 44%, saw their tumors shrink by 30% or more. Disease control hit 50% in the broader group.
The duration of response? Not reached. In oncology, that's the statistical equivalent of saying "we still can't see the finish line because patients keep responding." The longest ongoing response has been ticking past 18 months with no signs of stopping.
Median overall survival in the Phase 1b population was 15.2 months. In the high CD70 group, it hadn't been reached yet, meaning more than half those patients were still alive at the data cutoff.
The Side Effects: Real but Manageable
This isn't a free lunch. The safety profile reflects what you'd expect from intensive lymphodepletion (chemotherapy given before CAR-T to make room for the new cells) plus an active cellular therapy.
Cytokine release syndrome, the inflammatory storm that occurs when CAR-T cells activate, appeared in 68% of patients. The encouraging part: none of it was severe (Grade 3 or higher) in the Phase 1b cohort. Neurotoxicity showed up in 18% of patients, all mild to moderate.
The blood-related side effects were more significant. Grade 3 or higher neutropenia (dangerously low white blood cells) hit 68% of patients. A newer concern called IEC-HS, an inflammatory syndrome similar to a condition called HLH, occurred in 36% of patients. Most cases were mild, but two patients experienced high-grade events. The company developed a management protocol that appears to keep this under control.
Three on-study deaths occurred during the earlier Phase 1a portion of the study, of which one was considered treatment-related. None happened in Phase 1b, suggesting the optimized regimen and dosing are safer.
Wall Street's Measured Optimism
Analysts are treating the JCO publication as scientific validation rather than a commercial inflection point. The consensus rating on Allogene is Buy, with an average 12-month price target around $8.50, implying roughly 300%+ upside from recent levels. That's classic development-stage biotech math: enormous potential, enormous risk.
Piper Sandler maintains an Overweight rating. TD Cowen has called Allogene's broader pipeline data a "home run." But cautious voices, like H.C. Wainwright, flag execution risk and the company's ongoing need for capital.
The ALLO-316 data specifically is being treated as a platform de-risking event. If Allogene's gene-editing approach works in solid tumors (historically the hardest setting), it builds confidence that the technology can work across multiple targets and cancer types. CD70 is also expressed in lung cancer, glioblastoma, and several blood cancers, giving ALLO-316 potential beyond kidney cancer.
The Bigger Picture
One Phase 1 trial with 20 patients doesn't rewrite oncology textbooks. Responses need to hold up in larger studies, and the competitive landscape is fierce: Caribou Biosciences, Celyad, and others are racing with their own allogeneic approaches, while autologous CAR-T makers and newer modalities like bispecific antibodies and antibody-drug conjugates crowd the field.
But proof-of-concept matters enormously in a space defined by failure. For years, the question was whether any off-the-shelf CAR-T could produce durable responses in solid tumors. ALLO-316 just answered that question with a yes.
Now the harder question: can they do it at scale, in more patients, consistently enough to earn FDA approval? That's the castle that still needs storming. But for the first time, someone's gotten past the moat.
Deals & M&A4 min read
GSK Just Lit $700 Million on Fire in the Neuroscience Graveyard
GSK walked away from a $2.2 billion neuroscience deal with Alector after both antibody drugs flopped in clinical trials. The $700 million already spent is gone, and the wreckage says a lot about why brain diseases remain pharma's hardest problem.
